Union Therapeutics starts phase II trial of nasal spray for Covid-19 patients

Biotech company Union Therapeutics is testing its candidate niclosamid as a nasal spray for patients infected with Covid-19 who are either asymptomatic or mildly symptomatic in a phase II study.

Photo: Union Therapeutics / PR

The Danish biotech company Union Therapeutics has enrolled the first patient in its phase II trial of drug candidate niclosamid as a treatment for Covid-19 patients, it reports in a press release.

According to the company, the study's primary goal is to investigate whether niclosamid administered intranasally can prevent symptom progression in the enrolled patients who have been infected with Covid-19 but who have no symptoms or mild symptoms when they join the study.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs